Public offering

Independence Realty Trust, Inc. Announces Closing of Public Offering of 16,100,000 shares of Common Stock, Including Exercise in Full of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Friday, July 30, 2021
Residential Building & Real Estate, Construction & Property, REIT, Finance, Financial markets, Financial economics, Stock market, Corporate finance, Initial public offering, Ladenburg Thalmann, Security, Public offering

Independence Realty Trust, Inc. (NYSE: IRT) (IRT) today announced the closing of its previously announced underwritten public offering of 16,100,000 shares of common stock at a public offering price of $17.75 per share, including 2,100,000 shares sold pursuant to the exercise in full of the underwriters option to purchase additional shares of common stock.

Key Points: 
  • Independence Realty Trust, Inc. (NYSE: IRT) (IRT) today announced the closing of its previously announced underwritten public offering of 16,100,000 shares of common stock at a public offering price of $17.75 per share, including 2,100,000 shares sold pursuant to the exercise in full of the underwriters option to purchase additional shares of common stock.
  • Regions Securities LLC, Ramirez & Co., Inc., Comerica Securities, Compass Point, Ladenburg Thalmann and Bancroft Capital acted as co-managers for the offering.
  • IRT will not initially receive any proceeds from the sale of shares of its common stock by the forward purchaser or its affiliate in the offering.
  • A registration statement relating to the offered securities has been declared effective by the Securities and Exchange Commission.

Bionomics Announces Plans to Conduct U.S. Initial Public Offering

Retrieved on: 
Monday, August 2, 2021
Finance, Financial markets, Financial economics, ADSS, American depositary receipt, OTC Markets Group, Public offering, Initial public offering

ADELAIDE, Australia, Aug. 2, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF), (Bionomics) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares (ADSs) in the United States and a concurrent listing of ADSs on Nasdaq.

Key Points: 
  • ADELAIDE, Australia, Aug. 2, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF), (Bionomics) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares (ADSs) in the United States and a concurrent listing of ADSs on Nasdaq.
  • The number of ADSs and price of the proposed offering have not yet been determined.
  • Each ADS would represent a certain number of fully paid ordinary shares in Bionomics.
  • All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our plans to conduct a registered initial public offering in the United States and the timing of the proposed offering.

Rani Therapeutics Announces Pricing of Initial Public Offering

Initial public offering, Financial economics, Finance, Money, Corporate finance, Actuarial science, Underwriting, Public offering, Stock market

SAN JOSE, Calif., July 30, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Rani Therapeutics or Rani), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics, today announced the pricing of its initial public offering of 6,666,667 shares of Class A common stock at a price to the public of $11.00 per share.

Key Points: 
  • SAN JOSE, Calif., July 30, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Rani Therapeutics or Rani), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics, today announced the pricing of its initial public offering of 6,666,667 shares of Class A common stock at a price to the public of $11.00 per share.
  • The gross proceeds to Rani from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be$73.3 million.
  • In addition, Rani has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of Class A common stock at the initial public offering price, less underwriting discounts and commissions.
  • Rani Therapeutics is a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics.

IN8bio Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, July 30, 2021
Finance, Financial markets, Initial public offering, Financial economics, Corporate finance, Stock market, Underwriting, Public offering, Gross spread

NEW YORK, July 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies utilizing its DeltEx platform (IN8bio or the Company), today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $10.00 per share, for gross proceeds of $40 million, before underwriting discounts and commissions and estimated offering expenses.

Key Points: 
  • NEW YORK, July 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies utilizing its DeltEx platform (IN8bio or the Company), today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $10.00 per share, for gross proceeds of $40 million, before underwriting discounts and commissions and estimated offering expenses.
  • The offering is expected to close on August 3, 2021, subject to satisfaction of customary closing conditions.
  • In addition, IN8bio has granted the underwriter a 30-day option to purchase up to an additional 600,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.
  • A registration statement related to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on July 29, 2021.

Immuneering Announces Pricing of Upsized Initial Public Offering

Retrieved on: 
Friday, July 30, 2021
Finance, Financial markets, Financial economics, Corporate finance, Stock market, Initial public offering, Underwriting, Public offering, Stock, NASDAQ

CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced the pricing of its upsized initial public offering of 7,500,000 shares of Class A common stock at a public offering price of $15.00 per share, for total gross proceeds of $112.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering.

Key Points: 
  • CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced the pricing of its upsized initial public offering of 7,500,000 shares of Class A common stock at a public offering price of $15.00 per share, for total gross proceeds of $112.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering.
  • All of the Class A common stock is being offered by Immuneering.
  • The offering is expected to close on August 3, 2021, subject to customary closing conditions.
  • In addition, Immuneering has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of its Class A common stock at the initial public offering price less the underwriting discounts and commissions.

RxSight, Inc. Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, July 30, 2021
Finance, Financial economics, Financial markets, Initial public offering, Corporate finance, Stock market, Underwriting, Public offering, Red herring prospectus

ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16.00 per share.

Key Points: 
  • ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16.00 per share.
  • The gross proceeds to RxSight from the offering are expected to be $117.6 million, before deducting underwriting discounts and commissions and offering expenses.
  • In addition, RxSight has granted the underwriters a 30-day option to purchase up to an additional 1,102,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
  • This press release contains forward-looking statements, including with respect to the proposed initial public offering.

HealthCare Royalty, Inc. Launches Initial Public Offering

Retrieved on: 
Thursday, July 29, 2021
Financial markets, Finance, Financial economics, Corporate finance, Stock market, Equity securities, Initial public offering, Stock, Par value, NASDAQ, Common stock, Public offering

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- HealthCare Royalty, Inc. (together with its subsidiaries, HCR or the Company) today announced that it has commenced the roadshow for its initial public offering of46,875,000 shares of its Class A common stock, par value $0.01 per share (Class A Common Stock), at an anticipated public offering price between $15.00 and $17.00 per share.

Key Points: 
  • NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- HealthCare Royalty, Inc. (together with its subsidiaries, HCR or the Company) today announced that it has commenced the roadshow for its initial public offering of46,875,000 shares of its Class A common stock, par value $0.01 per share (Class A Common Stock), at an anticipated public offering price between $15.00 and $17.00 per share.
  • HCR is offering 31,250,000 shares of Class A Common Stock, and the selling stockholder is offering an additional 15,625,000 shares of Class A Common Stock.
  • The Companys Class A Common Stock is expected to be listed for trading on the Nasdaq Global Market under the symbol HCRX.
  • Siebert Williams Shank, Cabrera Capital Markets LLC and Drexel Hamilton are acting as co-managers for the proposed offering.

Minim Announces Pricing of $25 Million Public Offering of Common Stock

Retrieved on: 
Thursday, July 29, 2021
Finance, Money, Financial markets, Initial public offering, Stock market, Corporate finance, MINIM, MINIM, Public offering, Security, NASDAQ, Offering

MANCHESTER, NH, July 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Minim, Inc. (NASDAQ: MINM) (the Company) today announced the pricing of an underwritten public offering of 10,000,000 shares of the Companys common stock at a public offering price of $2.50 per share for aggregate gross proceeds of approximately $22.7 million after deducting underwriting discounts, commissions, and other offering expenses.

Key Points: 
  • MANCHESTER, NH, July 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Minim, Inc. (NASDAQ: MINM) (the Company) today announced the pricing of an underwritten public offering of 10,000,000 shares of the Companys common stock at a public offering price of $2.50 per share for aggregate gross proceeds of approximately $22.7 million after deducting underwriting discounts, commissions, and other offering expenses.
  • The offering is expected to close on or around August 2, 2021, subject to satisfaction of customary closing conditions.
  • B. Riley Securities is acting as the sole book-running manager and Northland Capital Markets is acting as co-manager for the offering.
  • Minim cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made.

Tenaya Therapeutics Announces Pricing of Upsized Initial Public Offering

Retrieved on: 
Friday, July 30, 2021
Biotechnology, General Health, Health, Genetics, Cardiology, Initial public offering, Finance, Financial economics, Money, Corporate finance, Underwriting, Public offering, Stock market

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced today the pricing of its underwritten, upsized initial public offering of 12,000,000 shares of its common stock at an initial public offering price of $15.00 per share.

Key Points: 
  • Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced today the pricing of its underwritten, upsized initial public offering of 12,000,000 shares of its common stock at an initial public offering price of $15.00 per share.
  • All of the shares in the offering are being offered by Tenaya.
  • The gross proceeds to Tenaya from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $180.0 million.
  • In addition, Tenaya has granted the underwriters a 30-day option to purchase up to 1,800,000 additional shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

Dole plc Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, July 30, 2021
Food, Beverage, Retail, Finance, Financial markets, Money, Stock market, Initial public offering, Corporate finance, Underwriting, Goldman Sachs, Public offering, Security, Red herring prospectus

Dole plc, a newly created company formed for the combination of Total Produce plc and Dole Food Company, Inc., announced today the pricing of its initial public offering of 25,000,000 ordinary shares at a price of $16.00 per share.

Key Points: 
  • Dole plc, a newly created company formed for the combination of Total Produce plc and Dole Food Company, Inc., announced today the pricing of its initial public offering of 25,000,000 ordinary shares at a price of $16.00 per share.
  • The ordinary shares are being offered by Dole plc for total gross proceeds of $400 million, before deducting underwriting discounts and commissions and offering expenses.
  • In addition, the underwriters have been granted a 30-day option to purchase up to an additional 3,750,000 ordinary shares at the initial public offering price, less underwriting discounts and commissions.
  • Goldman Sachs & Co. LLC, Deutsche Bank Securities and Davy are acting as lead book-running managers for the offering.